Intel got crushed Thursday night. The stock fell hard, down 6% in after-hours trading, after the company posted a brutal first-quarter forecast. This came rightIntel got crushed Thursday night. The stock fell hard, down 6% in after-hours trading, after the company posted a brutal first-quarter forecast. This came right

Intel's stock dropped 6% after weak Q1 revenue and profit forecast.

Intel got crushed Thursday night. The stock fell hard, down 6% in after-hours trading, after the company posted a brutal first-quarter forecast.

This came right after it beat Wall Street estimates for Q4, which you’d think would help. It didn’t. The moment investors saw the weak Q1 guidance, they hit the sell button fast.

For the fourth quarter, Intel posted 15 cents per share in adjusted earnings, blowing past the 8 cents that Wall Street expected. Revenue came in at $13.7 billion, also ahead of the $13.4 billion estimate. But the company said it expects Q1 revenue between $11.7 billion and $12.7 billion, with breakeven adjusted EPS. That’s worse than what analysts were expecting: 5 cents per share on $12.51 billion in sales.

Intel reveals $600 million loss as foundry optimism fades

The company reported a net loss of $600 million, or 12 cents per share, for the quarter. That’s a big jump from the $100 million loss or 3 cents per share it posted during the same period last year.

Investors had been betting heavily on Intel, with the stock up 147% in the past year, mostly thanks to hope that its foundry unit would finally get a serious outside client. But now that hope’s running on fumes.

CEO Lip-Bu Tan had previously said the company’s 18A manufacturing technology “over-delivered” last year. That’s the same node meant to compete with TSMC’s 2nm process. He claimed the tech was good enough to start volume production, including for Intel’s Core Ultra Series 3 CPUs.

Lip-Bu said the company was “working aggressively” to ramp up 18A supply to meet “strong customer demand.” But there’s no big customer yet, and that’s what’s killing the buzz.

Finance boss David Zinsner told CNBC that customers for the next-gen 14A node would appear in the second half of 2026. He didn’t name any names and didn’t sound too confident they’d be revealed publicly. “Once we get them, we’re gonna need to start really spending capital on the 14A front, and that’s how you’ll know,” Zinsner said.

He also blamed the bad Q1 guidance on low inventory, saying Intel didn’t have enough supply for typical seasonal demand. So, not only is the foundry business still stuck waiting on clients, but it’s not even ready to meet orders when they come in.

AI server chips rise, laptop chips fall, and Nvidia buys in

There was some growth in Intel’s Data Center and AI segment, which made $4.7 billion this quarter. That’s a 9% jump from last year. Analysts said it’s tied to more spending on AI infrastructure, and Lip-Bu agreed, saying Intel’s CPUs are playing a bigger role in powering systems for artificial intelligence.

But while server chips went up, laptop chips didn’t. The Client Computing Group, which handles chips for PCs, fell 7% year-over-year, dropping to $8.2 billion in revenue.

The foundry division brought in $4.5 billion, though that figure includes chips Intel made for itself. No one’s buying the hype until they land outside clients. Right now, it’s all internal shuffling.

During 2025, Nvidia, SoftBank, and even the U.S. government poured money into the company. Intel confirmed that it completed a $5 billion stock sale to Nvidia during the quarter, making Nvidia a major shareholder.

The rest of the market looked a little better on Thursday. Stocks rallied as geopolitical fears eased. The Dow Jones gained 306.78 points to close at 49,384.01. The S&P 500 rose 0.55% to 6,913.35, and the Nasdaq ended at 23,436.02, up 0.91%, lifted by gains in Nvidia, Microsoft, and Meta. But those gains didn’t help Intel, which got hammered anyway.

Even with the broader rally, the S&P 500 is down 0.4% for the week, and the Nasdaq is off 0.3%. Only the Dow is still clinging to a small weekly gain.

Want your project in front of crypto’s top minds? Feature it in our next industry report, where data meets impact.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26